Change of company name for Biovitrum AB (publ)

Biovitrum AB (publ) will be listed under its new company name, Swedish Orphan
Biovitrum AB (publ) with effect from June 24, 2010.

+-----------------------+------------+
|New short name:        |SOBI        |
+-----------------------+------------+
|Unchanged ISIN code:   |SE0000872095|
+-----------------------+------------+
|Unchanged Round lot:   |1           |
+-----------------------+------------+
|Unchanged orderbook ID:|36316       |
+-----------------------+------------+




For more information please contact: Swedish Orphan Biovitrum AB (publ)

Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@sobi.com


About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease patients
with high medical needs. The portfolio consists of about 60 marketed products
and an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care.
Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and
approximately 500 employees. The head office is located in Sweden and the share
(STO:BVT ) is listed on NASDAQ OMX Stockholm. For more information please
visitwww.sobi.com.

Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on June 21, 2010 at 4  p.m. CET.